Nemaura Medical Inc
(FRA:N18A)
€
0.115
0 (0%)
Market Cap: 2.11 Mil
Enterprise Value: 19.96 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 23/100 Nemaura Medical Inc Positive Results from Head-to-Head Study with Major CGM Call Transcript
May 10, 2020 / NTS GMT
Dave Gentry
RedChip Companies, Inc. - Analyst
Back to Chowdhury. Thanks for being with us today.
Faz Chowdhury
Nemaura Medical Inc. - CEO & Chairman of the Board
That's my pleasure.
Questions & Answers
Dave Gentry
RedChip Companies, Inc. - Analyst
And you recently announced a head-to-head study with one of the major incumbents in the continuous glucose monitoring space. What can you tell us about the study?
Faz Chowdhury
Nemaura Medical Inc. - CEO & Chairman of the Board
Yes. So let me give you some background as to why we decided to start these studies. We've had discussions with a number of health insurers. Because, of course, our target is to get product reimbursement. Now when we look at the existing CGM, whether it's Dexcom or the Abbott, you've got CGMs that last for up to 10 days at a time for 14 days aside. And what we have seen is that based on anecdotal evidence, whereby individuals that have done intensive monitoring using finger prick
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot